☰

Eugine Lee, Ph.D. - Publications

Affiliations: 
2014 Basic Medical Science New York University, New York, NY, United States 
Area:
Cell Biology
Tree Info Similar researchers PubMed Report error

11 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Zhang Z, Karthaus WR, Lee YS, Gao VR, Wu C, Russo JW, Liu M, Mota JM, Abida W, Linton E, Lee E, Barnes SD, Chen HA, Mao N, Wongvipat J, et al. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell. PMID 32679108 DOI: 10.1016/J.Ccell.2020.06.005  0.673
2020 Watson PA, Lawrence KE, Nadkarni TV, Ishmael TF, Lee E, Rivera ACA, Love JR, Wongvipat J, Cai L, Nazir A, Iaquinta PJ, Chang K, Liang Y, Hannon GJ, Sawyers CL. Abstract 3430: The protein phosphatase 4 complex is a tumor suppressor in prostate cancer Cancer Research. 80: 3430-3430. DOI: 10.1158/1538-7445.Am2020-3430  0.541
2019 Lee E, Wongvipat J, Choi D, Wang P, Lee YS, Zheng D, Watson PA, Gopalan A, Sawyers CL. amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance. Elife. 8. PMID 30644358 DOI: 10.7554/Elife.41913  0.659
2019 Zhang Z, Karthaus W, Mota JM, Mu P, Wu C, Abida W, Linton E, Lee YS, Lee E, Mao N, Adams E, Choi D, Rathkopf DE, Carver B, Gopalan A, et al. Abstract 111: Tumor microenvironment derived NRG1 promotes antiandrogen resistance in prostate cancer Cancer Research. 79: 111-111. DOI: 10.1158/1538-7445.Am2019-111  0.669
2018 Lee E, Wongvipat J, Choi D, Wang P, Lee YS, Zheng D, Watson PA, Gopalan A, Sawyers CL. Author response: GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance Elife. DOI: 10.7554/Elife.41913.036  0.669
2015 Lee E, Ha S, Logan SK. Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells. Plos One. 10: e0141589. PMID 26509262 DOI: 10.1371/Journal.Pone.0141589  0.75
2015 Lee E, Ha S, Logan S. MP66-08 DUAL PATHWAY INHIBITION IN PROSTATE CANCER Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2361  0.724
2013 Lee E, Madar A, David G, Garabedian MJ, Dasgupta R, Logan SK. Inhibition of androgen receptor and β-catenin activity in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 110: 15710-5. PMID 24019458 DOI: 10.1073/Pnas.1218168110  0.749
2013 Kirshenbaum K, Levine P, Lee E, Imberg-Kazdan K, Logan S, Garabedian M. 981 TARGETING ANDROGEN RECEPTOR-DEPENDENT PROSTATE CANCER WITH MULTIVALENT ETHISTERONE CONJUGATES Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.563  0.759
2013 Lee E, Garabedian M, DasGupta R, Logan S. 796 INHIBITION OF ANDROGEN RECEPTOR AND BETA-CATENIN ACTIVITY IN PROSTATE CANCER Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.360  0.714
2012 Levine PM, Lee E, Greenfield A, Bonneau R, Logan SK, Garabedian MJ, Kirshenbaum K. Androgen receptor antagonism by divalent ethisterone conjugates in castrate-resistant prostate cancer cells. Acs Chemical Biology. 7: 1693-701. PMID 22871957 DOI: 10.1021/Cb300332W  0.712
Show low-probability matches.